IDEAS home Printed from https://ideas.repec.org/a/dbk/health/v4y2025ip626id626.html
   My bibliography  Save this article

Efficacy and Safety of Hydroxychloroquine for the Treatment of COVID-19: An empirical study

Author

Listed:
  • Saraswat
  • Patro
  • Rampal
  • Sirisha
  • Sharma
  • Monika

Abstract

The new coronavirus disease epidemic of 2019 (COVID-19) has spread worldwide. A quick solution to meet the urgent demand for effective treatment may be drug repurposing. To treat COVID-19, evaluated the clinical effectiveness of hydroxychloroquine and chloroquine. The individuals that received a modest COVID-19 score were randomized to obtain the control therapy or hydroxychloroquine 800 milligrams once daily on Day 7 and 250 milligrams for nine days, except the evaluated the clinical effectiveness of hydrochloride and chlorin equine. Compared to the control group (CtrlGrp) (Group 3), adverse reactions were observed more frequently in those taking chloroquine (Group 1) and hydroxychloroquine (Group 2). The time to clinical recovery (TTCR) was shortened in the Group 1 relation to the CtrlGrp. In the Group 2, there was a tendency toward lower TTCR. Chloroquine and Group 2 reached viral RNA negative substantially faster than the CtrlGrp. The typical instances to become RNA negative in the groups treated with chloroquine, hydroxychloroquine, and controls comprised two days, two weeks, and seven days, correspondingly. Both the length of hospitalization and the results of the lung computed tomography (CT) indicated improvements in the hydroxychloroquine and chloroquine pharmacologic categories. This research provides evidence that hydrochlorothiazide may be used to treat mild COVID-19, and it complements more excellent investigations.

Suggested Citation

Handle: RePEc:dbk:health:v:4:y:2025:i::p:626:id:626
DOI: 10.56294/hl2025626
as

Download full text from publisher

To our knowledge, this item is not available for download. To find whether it is available, there are three options:
1. Check below whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a
for a similarly titled item that would be available.

More about this item

Statistics

Access and download statistics

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:dbk:health:v:4:y:2025:i::p:626:id:626. See general information about how to correct material in RePEc.

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

We have no bibliographic references for this item. You can help adding them by using this form .

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Javier Gonzalez-Argote (email available below). General contact details of provider: https://hl.ageditor.ar/ .

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.